These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

977 related items for PubMed ID: 7492293

  • 1. Complementary positron emission tomographic studies of the striatal dopaminergic system in Parkinson's disease.
    Antonini A, Vontobel P, Psylla M, Günther I, Maguire PR, Missimer J, Leenders KL.
    Arch Neurol; 1995 Dec; 52(12):1183-90. PubMed ID: 7492293
    [Abstract] [Full Text] [Related]

  • 2. Complementary PET studies of striatal neuronal function in the differential diagnosis between multiple system atrophy and Parkinson's disease.
    Antonini A, Leenders KL, Vontobel P, Maguire RP, Missimer J, Psylla M, Günther I.
    Brain; 1997 Dec; 120 ( Pt 12)():2187-95. PubMed ID: 9448574
    [Abstract] [Full Text] [Related]

  • 3. Striatal glucose metabolism and dopamine D2 receptor binding in asymptomatic gene carriers and patients with Huntington's disease.
    Antonini A, Leenders KL, Spiegel R, Meier D, Vontobel P, Weigell-Weber M, Sanchez-Pernaute R, de Yébenez JG, Boesiger P, Weindl A, Maguire RP.
    Brain; 1996 Dec; 119 ( Pt 6)():2085-95. PubMed ID: 9010012
    [Abstract] [Full Text] [Related]

  • 4. Long-term changes of striatal dopamine D2 receptors in patients with Parkinson's disease: a study with positron emission tomography and [11C]raclopride.
    Antonini A, Schwarz J, Oertel WH, Pogarell O, Leenders KL.
    Mov Disord; 1997 Jan; 12(1):33-8. PubMed ID: 8990051
    [Abstract] [Full Text] [Related]

  • 5. Levodopa-induced changes in synaptic dopamine in patients with Parkinson's disease as measured by [11C]raclopride displacement and PET.
    Tedroff J, Pedersen M, Aquilonius SM, Hartvig P, Jacobsson G, Långström B.
    Neurology; 1996 May; 46(5):1430-6. PubMed ID: 8628494
    [Abstract] [Full Text] [Related]

  • 6. Regional striatal DOPA transport and decarboxylase activity in Parkinson's disease.
    Kuwabara H, Cumming P, Yasuhara Y, Léger GC, Guttman M, Diksic M, Evans AC, Gjedde A.
    J Nucl Med; 1995 Jul; 36(7):1226-31. PubMed ID: 7790948
    [Abstract] [Full Text] [Related]

  • 7. Monosymptomatic resting tremor and Parkinson's disease: a multitracer positron emission tomographic study.
    Ghaemi M, Raethjen J, Hilker R, Rudolf J, Sobesky J, Deuschl G, Heiss WD.
    Mov Disord; 2002 Jul; 17(4):782-8. PubMed ID: 12210876
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Striatal D2 receptor status in patients with Parkinson's disease, striatonigral degeneration, and progressive supranuclear palsy, measured with 11C-raclopride and positron emission tomography.
    Brooks DJ, Ibanez V, Sawle GV, Playford ED, Quinn N, Mathias CJ, Lees AJ, Marsden CD, Bannister R, Frackowiak RS.
    Ann Neurol; 1992 Feb; 31(2):184-92. PubMed ID: 1575457
    [Abstract] [Full Text] [Related]

  • 10. Increased density of dopamine D2 receptors in the putamen, but not in the caudate nucleus in early Parkinson's disease: a PET study with [11C]raclopride.
    Rinne JO, Laihinen A, Ruottinen H, Ruotsalainen U, Någren K, Lehikoinen P, Oikonen V, Rinne UK.
    J Neurol Sci; 1995 Oct; 132(2):156-61. PubMed ID: 8543941
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Dopamine storage capacity in caudate and putamen of patients with early Parkinson's disease: correlation with asymmetry of motor symptoms.
    Kumakura Y, Gjedde A, Danielsen EH, Christensen S, Cumming P.
    J Cereb Blood Flow Metab; 2006 Mar; 26(3):358-70. PubMed ID: 16079784
    [Abstract] [Full Text] [Related]

  • 18. The relation of putamen and caudate nucleus 18F-Dopa uptake to motor and cognitive performances in Parkinson's disease.
    Broussolle E, Dentresangle C, Landais P, Garcia-Larrea L, Pollak P, Croisile B, Hibert O, Bonnefoi F, Galy G, Froment JC, Comar D.
    J Neurol Sci; 1999 Jul 01; 166(2):141-51. PubMed ID: 10475108
    [Abstract] [Full Text] [Related]

  • 19. Corticostriatal covariance patterns of 6-[18F]fluoro-L-dopa and [18F]fluorodeoxyglucose PET in Parkinson's disease.
    Kaasinen V, Maguire RP, Hundemer HP, Leenders KL.
    J Neurol; 2006 Mar 01; 253(3):340-8. PubMed ID: 16222426
    [Abstract] [Full Text] [Related]

  • 20. The metabolic anatomy of Parkinson's disease: complementary [18F]fluorodeoxyglucose and [18F]fluorodopa positron emission tomographic studies.
    Eidelberg D, Moeller JR, Dhawan V, Sidtis JJ, Ginos JZ, Strother SC, Cedarbaum J, Greene P, Fahn S, Rottenberg DA.
    Mov Disord; 1990 Mar 01; 5(3):203-13. PubMed ID: 2117706
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 49.